Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect

References

• Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 2012;15:21–38
   PubMed Web of Science ®Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615–27
   PubMed Web of Science ®Google Scholar
• Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005;14:35–48
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Giglioni B, Min E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861–79
   PubMed Web of Science ®Google Scholar
• Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review. Taiwan J Obstet Gynecol 2009;48:239–44
   PubMed Web of Science ®Google Scholar
• Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 2007;39:267–74
   PubMed Web of Science ®Google Scholar
• Gillies R, Raghunand N, Garcia-Martin M, Gateby R. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Magn 2004;23:57–64
   PubMedGoogle Scholar
• De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005;1:779–86
   PubMedGoogle Scholar
• Smallbone K, Gatenby RA, Maini P. Mathematical modeling of tumour acidity. J Theor Biol 2008;255:106–12
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Sonveaux P, Stock C, et al. Proton channels and exchangers in cancer. Biochim Biophys Acta 2014. [Epub ahead of print]. doi: 10.1016/j.bbamem.2014.10.015
   PubMed Web of Science ®Google Scholar
• Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 2011;8:2032–8
   PubMed Web of Science ®Google Scholar
• Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets 2011;11:613–23
   PubMed Web of Science ®Google Scholar
• Bailey KM, Wojtkowiak JW, Hashim AI, Gillies RJ. Targeting the metabolic microenvironment of tumors. Adv Pharmacol 2012;65:63–107
   PubMedGoogle Scholar
• Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res 2010;29:44
   PubMed Web of Science ®Google Scholar
• Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006;5:1275–9
   PubMed Web of Science ®Google Scholar
• Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Met Rev 2014;33:1095–108
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19:25–35
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004;96:1702–13
   PubMed Web of Science ®Google Scholar
• De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother 2005;6:1049–54
   PubMed Web of Science ®Google Scholar
• De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007;67:5408–17
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Baldi A, Buglioni S, et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011;9:221
   PubMed Web of Science ®Google Scholar
• Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med 2013;11:268
   PubMed Web of Science ®Google Scholar
• Bellone M, Calcinotto A, Filipazzi P, et al. The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. Oncoimmunology 2013;2:e22058
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Buglioni S, Carocci F, et al. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014;12:225
   PubMed Web of Science ®Google Scholar
• Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett 2015;356:697–703
   PubMed Web of Science ®Google Scholar
• Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 2004;94:106–11
   PubMed Web of Science ®Google Scholar
• Kromer W, Krüger U, Huber R, et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998;56:57–70
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000;38:243–70
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935–51
   PubMed Web of Science ®Google Scholar
• Geran RI, Greenberg NH, Macdonald MM, et al. Protocols for screening chemical agents and natural products against animal tumours and natural other biological systems. Cancer Chemother Rep 1972;3:59–61
   Google Scholar
• Morton DB, Griffiths PH. Guidelines on the recognition of pain, distress and discomfort in experimental animals and a hypothesis for assessment. Vet Rec 1985;116:431–6
   PubMed Web of Science ®Google Scholar
• De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010;127:207–19
   PubMed Web of Science ®Google Scholar
• Kunkle B, Yoo C, Roy D. Discovering gene–environment interactions in glioblastoma through a comprehensive data integration bioinformatics method. Neurotoxicology 2013;35:1–14
   PubMed Web of Science ®Google Scholar
• Tounekti O, Pron G, Belehradek J Jr, Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993;53:5462–9
   PubMed Web of Science ®Google Scholar
• Pron G, Mahrour N, Orlowski S, et al. Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 1999;57:45–56
   PubMed Web of Science ®Google Scholar
• Doshi G, Sonpavde G, Sternberg CN. Clinical and pharmacokinetic evaluation of satraplatin. Expert Opin Drug Metab Toxicol 2012;8:103–11
   PubMed Web of Science ®Google Scholar
• Quéreux G, Dréno B. Fotemustine for the treatment of melanoma. Expert Opin Pharmacother 2011;12:2891–904
   PubMed Web of Science ®Google Scholar
• Lozupone F, Pende D, Burgio VL, et al. Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 2004;64:378–85
   PubMed Web of Science ®Google Scholar
• Edwards MP, Price DA. Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks. Ann Rep Med Chem 2010;45:381–91
   Web of Science ®Google Scholar
• Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881–90
   PubMed Web of Science ®Google Scholar
• Eisenberg D, McLachlan AD. Solvation energy in protein folding and binding. Nature 1986;319:199–203
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Kollman PA. What determines the strength of noncovalent association of ligands to proteins in aqueous solution? Proc Natl Acad Sci USA 1993;90:8402–6
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012;72:2746–56
   PubMed Web of Science ®Google Scholar
• Stadler S, Weina K, Gebhardt C, Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci 2014;60:83–8
   PubMed Web of Science ®Google Scholar
• Spagnolo F, Ghiorzo P, Orgiano L, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 2015;8:157–68
   PubMed Web of Science ®Google Scholar
• Costa-Rodrigues J, Reis S, Teixeira S, et al. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 2013;280:5052–64
   PubMed Web of Science ®Google Scholar
• Garrido W, Rocha JD, Jaramillo C, et al. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme. Curr Drug Targets 2014;15:931–42
   PubMed Web of Science ®Google Scholar
• Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 2014;23:1985–96
   PubMed Web of Science ®Google Scholar
• Grandane A, Tanc M, Zalubovskis R, Supuran CT. 6-Triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrases IX and XII. Bioorg Med Chem Lett 2014;24:1256–60
   PubMed Web of Science ®Google Scholar
• Grandane A, Tanc M, Zalubovskis R, Supuran CT. Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem 2014;22:1522–8
   PubMed Web of Science ®Google Scholar